Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNA7 | P36544 | 4/20 | 0.47 |
| ▸ | LIPG | Q9Y5X9 | 1/20 | 0.41 |
| ▸ | ROCK2 | O75116 | 3/20 | 0.41 |
| ▸ | GPR88 | Q9GZN0 | 2/20 | 0.41 |
| ▸ | KCNQ3 | O43525 | 2/20 | 0.40 |
| ▸ | KCNQ2 | O43526 | 2/20 | 0.40 |
| ▸ | PRKG1 | Q13976 | 1/20 | 0.40 |
| ▸ | ABL1 | P00519 | 1/20 | 0.39 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.39 |
| ▸ | KCNQ4 | P56696 | 1/20 | 0.39 |
| ▸ | KCNQ5 | Q9NR82 | 1/20 | 0.39 |
| ▸ | KIT | P10721 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5849152 | 1.00 | CHRNA7 (0.47) | CHRNA7LIPGROCK2GPR88KCNQ3 | |
| SCHEMBL30795863 | 0.89 | CYP3A4 (0.47) | CHRNA7LIPGROCK2PRKG1 | |
| SCHEMBL5849183 | 0.89 | CYP3A4 (0.47) | CHRNA7LIPGROCK2PRKG1 | |
| SCHEMBL15807217 | 0.80 | KCNQ3 (0.57) | CHRNA7GPR88KCNQ3KCNQ2KCNQ4 | |
| SCHEMBL5847724 | 0.78 | CHRNA7 (0.55) | CHRNA7ROCK2GPR88KCNQ3KCNQ2 | |
| SCHEMBL30795745 | 0.78 | CHRNA7 (0.55) | CHRNA7ROCK2GPR88KCNQ3KCNQ2 | |
| SCHEMBL5888450 | 0.76 | ROCK2 (0.49) | LIPGROCK2PRKG1 | |
| SCHEMBL5888445 | 0.76 | ROCK2 (0.49) | LIPGROCK2PRKG1 | |
| SCHEMBL5848169 | 0.76 | ACKR3 (0.42) | LIPGROCK2GPR88PRKG1 | |
| SCHEMBL30824709 | 0.76 | ACKR3 (0.42) | LIPGROCK2GPR88PRKG1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4584250-A1 | COMBINATION THERAPIES INCLUDING METAL CHANNEL ACTIVATORS | Biohaven Therapeutics Ltd. (VG) | 2025-07-16 | — | — | EP | disclosed |
| EP-4580679-A1 | COMBINATION THERAPIES INCLUDING METAL CHANNEL ACTIVATORS AND NMDA RECEPTOR ANTAGONISTS | Biohaven Therapeutics Ltd. (VG) | 2025-07-09 | — | — | EP | disclosed |
| WO-2024054811-A1 | COMBINATION THERAPIES INCLUDING METAL CHANNEL ACTIVATORS | BIOHAVEN THERAPEUTICS LTD. (VG) | 2024-03-14 | — | — | WO | disclosed |
| WO-2024054807-A1 | COMBINATION THERAPIES INCLUDING METAL CHANNEL ACTIVATORS AND TDP-43 MODULATORS | BIOHAVEN THERAPEUTICS LTD. (VG) | 2024-03-14 | — | — | WO | disclosed |
| WO-2024050389-A1 | COMBINATION THERAPIES INCLUDING METAL CHANNEL ACTIVATORS AND NMDA RECEPTOR ANTAGONISTS | BIOHAVEN THERAPEUTICS LTD. (VG) | 2024-03-07 | — | — | WO | disclosed |